Digest Network Come funziona
Network
/
Società
AN
Non verificato

AN2 Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniSaluteScienza

42 comunicati stampa

Guarda tutti i comunicati
23/10/2026
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Finanza
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
21/10/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Eventi
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/10/2026
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Fiere
Eventi
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/09/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Salute
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/09/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Mercato azionario
Finanza
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
31/08/2026
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Mercato del lavoro
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Farmaceutica
Biotecnologia
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/06/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Sanità
Comunicazione
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Eventi
Web e Social Network
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0